Tisotumab vedotin is a tissue factor (TF)-directed ADC consisting of an anti-TF monoclonal antibody conjugated to MMAE via a cleavable linker, with a DAR of 4, and received FDA approval for treating adult patients with recurrent or metastatic cervical cancer in April 2024 (Administration FaD, 2025). The gene discussed is TF; the disease is cervical carcinoma.